Barclays PLC Has $153,000 Holdings in The Beauty Health Company (NASDAQ:SKIN)

Barclays PLC lifted its position in shares of The Beauty Health Company (NASDAQ:SKIN) by 224.7% during the 3rd quarter, HoldingsChannel reports. The fund owned 106,103 shares of the company’s stock after purchasing an additional 73,425 shares during the period. Barclays PLC’s holdings in Beauty Health were worth $153,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Cohen Capital Management Inc. raised its position in Beauty Health by 344.1% in the third quarter. Cohen Capital Management Inc. now owns 572,848 shares of the company’s stock valued at $825,000 after purchasing an additional 443,859 shares during the last quarter. Federated Hermes Inc. raised its holdings in Beauty Health by 349,616.0% in the 2nd quarter. Federated Hermes Inc. now owns 370,699 shares of the company’s stock valued at $712,000 after buying an additional 370,593 shares during the last quarter. HighTower Advisors LLC bought a new position in Beauty Health in the 3rd quarter valued at approximately $121,000. Bank of New York Mellon Corp boosted its position in Beauty Health by 24.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 348,108 shares of the company’s stock worth $668,000 after buying an additional 69,329 shares during the period. Finally, FMR LLC grew its holdings in Beauty Health by 0.3% during the 3rd quarter. FMR LLC now owns 18,603,037 shares of the company’s stock worth $26,788,000 after acquiring an additional 58,826 shares during the last quarter. Institutional investors own 93.26% of the company’s stock.

Beauty Health Price Performance

Beauty Health stock opened at $1.90 on Wednesday. The firm has a market cap of $235.83 million, a P/E ratio of -4.52 and a beta of 0.81. The stock’s 50 day moving average is $1.57 and its 200 day moving average is $1.62. The company has a debt-to-equity ratio of 9.23, a current ratio of 6.56 and a quick ratio of 5.57. The Beauty Health Company has a one year low of $0.91 and a one year high of $5.17.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group raised their price target on shares of Beauty Health from $1.25 to $1.75 and gave the company a “hold” rating in a research note on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, Beauty Health currently has an average rating of “Hold” and a consensus target price of $2.55.

About Beauty Health

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.